Navigation Links
Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium
Date:9/9/2011

SAN FRANCISCO, Sept. 9, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that positive results from the company's Phase 2 clinical study of NKTR-102 in patients with metastatic breast cancer were presented at the ASCO 2011 Breast Cancer Symposium in San Francisco, California.  NKTR-102 is a novel topoisomerase I inhibitor designed using Nektar's proprietary polymer conjugate technology, and is being developed in multiple tumor settings.  

"NKTR-102 exhibits a very high response rate and excellent clinical benefit rate in patients with metastatic breast cancer, and importantly, this anti-tumor activity is maintained in each of the poor prognosis subsets within the study," said presenter and NKTR-102 study investigator, Dr. Agustin Garcia, Associate Professor of Clinical Medicine at USC Norris Comprehensive Center.  "The data from the Phase 2 study also shows highly promising PFS of 5.3 months and OS of 13.1 months in the every three week dose schedule, which was also very well-tolerated.   As a novel topoisomerase I inhibitor in breast cancer, NKTR-102 holds great therapeutic potential and allows us to address the challenge of resistance in this setting.  The investigators look forward to the initiation of the Phase 3 BEACON study of NKTR-102 in patients with metastatic breast cancer."  

More than one million women worldwide are diagnosed with breast cancer every year and the disease is the leading cause of cancer-related death among women.(1)  

Highlights from the Phase 2 Clinical Data PresentationThe randomized Simon two-stage study of single-agent NKTR-102 evaluated two 145 mg/m2 dose schedules of NKTR-102, every two weeks (q14d) and every three weeks (q21d), in 70 metastatic breast cancer patients.  NKTR-102 achieved a confirmed objective response rate by RECIST of 29 percent.  In addition
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
4. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
7. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... and MUNICH , May 22, 2013 /PRNewswire/ ... marketer of transcatheter aortic valve implantation (TAVI) systems for the ... results of the J enaValve Eval U ation of ... Pa T ients with S E vere Ao R tic ... . JUPITER is a post-market registry to evaluate five-year long ...
(Date:5/22/2013)... 2013  Milliman, Inc., a premier global consulting and ... Milliman Medical Index (MMI), which measures the healthcare costs ... benefits through an employer-sponsored preferred provider organization (PPO) plan. ... 2013 is $22,030. "For the second ... a percentage basis was the lowest in the history ...
(Date:5/22/2013)... WALLINGFORD, Conn. , May 22, 2013 ... announced today it has launched the first-ever line of ... Medical Services. The line includes QuikClot ® EMS ... and QuikClot ® EMS Rolled Gauze™, all custom-designed ... alive until they can be transported to a hospital ...
Breaking Medicine Technology:First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 2First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 3First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 4Annual Healthcare Cost for a Typical American Family is $22,030 According to 2013 Milliman Medical Index 2Z-Medica Launches New Line of Hemostatic Agents for use in Emergency Medical Services 2
... MORRISTOWN, N.J. , May 4 Sagent Pharmaceuticals, ... leading global generic pharmaceutical manufacturer, have launched an exclusive collaboration to ... the United States . , ... Under the agreement, Actavis will develop, obtain U.S. ...
... Provides Significantly Better Pain Relief Compared to Component Doses; Study Goals and ... , , ... 4 QRxPharma (ASX: QRX and OTCQX: QRXPY) announced ... IR, an immediate-release Dual-Opioid pain therapy.  Required for New Drug Application (NDA) ...
Cached Medicine Technology:Sagent Pharmaceuticals and Actavis Enter Into Exclusive U.S. Development, Supply and Marketing Collaboration for a Portfolio of Specialty Injectable Pharmaceutical Products 2Sagent Pharmaceuticals and Actavis Enter Into Exclusive U.S. Development, Supply and Marketing Collaboration for a Portfolio of Specialty Injectable Pharmaceutical Products 3QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain 2QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain 3QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain 4QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain 5
(Date:5/22/2013)... May 22, 2013 DePuy Pinnacle ... DePuy Pinnacle Hip Replacement System continue to move forward ... Bernstein Liebhard LLP reports. According to an Order ... to produce monitoring reports associated with a 2007 criminal ... device marketing practices. Plaintiffs maintained in their ...
(Date:5/22/2013)... 22, 2013 Today, Zane Benefits, Inc. ... Insurance Exchange . Zane Benefits, which provides comprehensive and ... the leader in defined contribution plans and ... Benefits’ website, beginning in 2014 as part of the ... and small businesses will become available through new state ...
(Date:5/22/2013)... that hospitals may be reaping enormous income for ... bloodstream infections contracted in their intensive care units. ... in the American Journal of Medical Quality ... who develops an avoidable central line-associated bloodstream infection ... for than a similar infection-free patient. Moreover, hospitals ...
(Date:5/22/2013)... 2013 Registered Dietitian and Founder of Tatalou ... Tatalou.com sharing a recipe for making energy bars at home. ... Bars ,” takes a recipe modified from one recently ... “Every day it gets more and more difficult to understand ... “The size of the nutrition label continues to grow and ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Unknown to the ... area at 30 mph. Minutes before it struck, the ... the nearing threat. This gave them time to reach safety ... Data is proud to provide a product that will ... A Wheelock SAFEPATH® SP40S Emergency Evacuation System provides ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation 2Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation 3Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 3Health News:Hospitals profit when patients develop bloodstream infections 2Health News:Hospitals profit when patients develop bloodstream infections 3Health News:Hospitals profit when patients develop bloodstream infections 4Health News:How To "Make Your Own Healthy Energy Bars" 2Health News:Telcom & Data Introduces Wheelock SAFEPATH® SP40S Emergency Evacuation System, An Effective Office Tool to Protect Employees from Severe Weather Threats 2
... Feb. 20 /Xinhua-PRNewswire/ -- Venture Global Limited,unveils the ... pollution. With VEGO Power Blocker, cellphone users could ... Be Protected, VEGO Power Blocker Kills the Invisible ... VEGO Power Blocker is a piece of ultra-thinned ...
... first scientific evidence that deadly emerging diseases have ... the outbreaks main sources. They say new diseases ... the greatest threat to humans. Expansion of humans ... with wildlife are the reason, they say. Meanwhile, ...
... Anti-bleeding agent Trasylol tied to increased death, complications, studies ... new studies confirm an increased incidence of death and ... used to reduce bleeding during coronary artery bypass surgeries. ... over both the short- and long-term. , Trasylol,s German ...
... , , WEDNESDAY, Feb. 20 (HealthDay News) -- The time of day ... the difference between life and death. , Two new studies find ... weekends are more likely to die in the hospital than those ... acceptable, one researcher said. "We should not be treating patients ...
... heart disease had no ... risk factors, BALTIMORE, Feb. 20 In an effort to ... Foundation will,hold its annual Women,s Heart Health Fair on Tues., Feb. ... Mayor Sheila,Dixon has granted non-essential female workers two hours leave that ...
... put an end to toothaches, PHILADELPHIA, Feb. ... model, based in Philadelphia, announced that it is,expanding ... offering licensing,opportunities to qualifying dental practices, worldwide. This ... in advancing,affordable dental/health care available everywhere, to all., ...
Cached Medicine News:Health News:Venture Global Limited Introduces an Innovative Anti-Cellphone Radiation Sticker Named 'VEGO Power Blocker' 2Health News:Scientists make first map of emerging-disease hotpsots 2Health News:Scientists make first map of emerging-disease hotpsots 3Health News:More Evidence of Danger From Heart Surgery Drug 2Health News:More Evidence of Danger From Heart Surgery Drug 3Health News:In-Hospital Stroke Deaths Rise on Nights, Weekends 2Health News:In-Hospital Stroke Deaths Rise on Nights, Weekends 3Health News:Free Health Screenings Aim to Identify Risk of Heart Disease in Women 2Health News:Emergency Dentist 24/7(TM) Announces Worldwide Licensing Program 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: